MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.35
-0.35
-1.61%
After Hours: 21.35 0 0.00% 16:01 05/24 EDT
OPEN
21.25
PREV CLOSE
21.70
HIGH
21.63
LOW
21.18
VOLUME
377.52K
TURNOVER
0
52 WEEK HIGH
36.95
52 WEEK LOW
18.98
MARKET CAP
1.72B
P/E (TTM)
-194.2675
1D
5D
1M
3M
1Y
5Y
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Zacks · 05/06 15:01
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 13:45
Recap: Myriad Genetics Q1 Earnings
  Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:22
BRIEF-Myriad Genetics Reports First Quarter Revenue And Reiterates Guidance For 2022
reuters.com · 05/05 13:15
Myriad Genetics Non-GAAP EPS of -$0.03 beats by $0.06, revenue of $164.9M beats by $8.81M
Myriad Genetics press release (NASDAQ:MYGN): Q1 Non-GAAP EPS of -$0.03 beats by $0.06. Revenue of $164.9M (-4.7% Y/Y) beats by $8.81M. FY22 Outlook: Revenue guidance of $6700m-$700M vs consensus of
Seekingalpha · 05/05 13:06
Myriad Genetics Q1 EPS $(0.03) Beats $(0.07) Estimate, Sales $164.90M Beat $156.62M Estimate
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 50 percent increase over losses of $(0.06) per share from the
Benzinga · 05/05 13:05
Myriad Genetics Q1 Adjusted Loss Narrows, Revenue Declines; Reiterates 2022 Guidance
MT Newswires · 05/05 10:49
-- Earnings Flash (MYGN) MYRIAD GENETICS Reports Q1 EPS $-0.03, vs. Street Est of $-0.09
MT Newswires · 05/05 09:08
More
No Data
Learn about the latest financial forecast of MYGN. Analyze the recent business situations of Myriad Genetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
50.00%Hold
50.00%Under-perform
0.00%Sell
Analyst Price Target
The average MYGN stock price target is 23.33 with a high estimate of 27.00 and a low estimate of 18.00.
High27.00
Average23.33
Low18.00
Current 21.35
EPS
Actual
Estimate
-0.08-0.040.000.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 342
Institutional Holdings: 92.25M
% Owned: 114.82%
Shares Outstanding: 80.34M
TypeInstitutionsShares
Increased
64
3.00M
New
31
1.02M
Decreased
70
3.08M
Sold Out
23
355.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.88%
Healthcare Equipment & Supplies
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
S. Louise Phanstiel
President/Chief Executive Officer/Director
Paul Diaz
Chief Financial Officer/Treasurer
R. Bryan Riggsbee
Chief Operating Officer
Nicole Lambert
Chief Human Resource Officer
Jayne Hart
Senior Vice President
Maggie Ancona
Chief Technology Officer
Kevin Haas
Chief Scientific Officer
Dale Muzzey
Other
Mark Verratti
Other
Pamela Wong
Independent Director
Heiner Dreismann
Independent Director
Rashmi Kumar
Independent Director
Dennis Langer
Independent Director
Lee Newcomer
Independent Director
Colleen Reitan
Independent Director
Daniel Skovronsky
Independent Director
Daniel Spiegelman
No Data
No Data
About MYGN
Myriad Genetics, Inc. (Myriad) is a genetic testing and precision medicine company. Myriad is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can progress patient care. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. The Company's products include myRisk, BRACAnalysis, BRACAnalysis CDx myChoice CDx, Prolaris, EndoPredict, Foresight and Prequel.

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.